GI
ATHE

GAMMA Investing’s Alterity Therapeutics ATHE Stock Holding History

GAMMA Investing’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Buy
2,309
+453
+24% +$1.97K ﹤0.01% 3098
2026
Q1 		$6.46K Buy
1,856
+1,066
+135% +$3.61K ﹤0.01% 3266
2025
Q4 		$2.43K Buy
+790
New +$3.02K ﹤0.01% 3546

Other funds holding ATHE

GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

GAMMA Investing's ATHE Position: Q2 2026 in Review

GAMMA Investing increased its Alterity Therapeutics (ATHE) stake by 24% in Q2 2026, buying an estimated $1.97K and bringing the position to 2,309 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3098.

GAMMA Investing first reported a position in ATHE in Q4 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • GAMMA Investing held 2,309 shares of Alterity Therapeutics worth $12.4K as of Q2 2026.
  • GAMMA Investing bought 453 Alterity Therapeutics shares in Q2 2026, an estimated $1.97K.
  • Alterity Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3098 holding.
  • GAMMA Investing first reported a position in Alterity Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 5 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.